Home / FGF-23 / Recombinant Human FGF-23 Protein

Recombinant Human FGF-23 Protein

Catalog #: 2604-FG
19 Citations Datasheet / COA / SDS

Carrier Free

Catalog # Availability Size / Price Qty
2604-FG-025/CF

With Carrier

Catalog # Availability Size / Price Qty
2604-FG-025
Best Seller
Graph showing dose-dependent bioactivity of human FGF-23 protein
1 Image
Product Details
Citations (19)
FAQs
Supplemental Products
Reviews
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human FGF-23 Protein Summary

Product Specifications

Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using BaF3 mouse pro‑B cells transfected with human FGF RIIIc. The ED50 for this effect is 0.1‑0.4 µg/mL in the presence of Recombinant Mouse Klotho (Catalog # 1819-KL) and heparin.
Source
Mouse myeloma cell line, NS0-derived human FGF-23 protein
Tyr25-Ile251 (Arg179Gln), with a C-terminal 6-His tag
Accession #
Q9GZV9
N-terminal Sequence
Analysis
Tyr25
Predicted Molecular Mass
26.1 kDa
SDS-PAGE
29-34 kDa, reducing conditions

Product Datasheets

You must select a language.

x

2604-FG (with carrier)

Product Datasheet
COA
SDS

You must select a language.

x

2604-FG/CF (carrier free)

Product Datasheet
COA
SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

2604-FG

Formulation Lyophilized from a 0.2 μm filtered solution in MOPS, Na2SO4, EDTA and DTT with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, 2 to 8 °C under sterile conditions after reconstitution.

2604-FG/CF

Formulation Lyophilized from a 0.2 μm filtered solution in MOPS, Na2SO4, EDTA and DTT.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, 2 to 8 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity Graph showing dose-dependent bioactivity of human FGF-23 protein View Larger

Recombinant human FGF-23 (2604-FG) induces proliferation in BaF3 mouse pro-B cells transfected with human FGFR3 (IIIc). The ED50 for this effect is 0.1-0.4 μg/mL in the presence of recombinant mouse Klotho (1819-KL) and heparin.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: FGF-23

Fibroblast growth factor 23 (FGF‑23) is a 30‑32 kDa member of the FGF family, within a subfamily that also includes FGF‑19 and FGF‑21. FGF proteins contain a 120 amino acid (aa) core FGF domain that exhibits a beta ‑trefoil structure (1, 2). FGF‑19 subfamily members are highly diffusible molecules owing to their poor ECM/heparin sulfate binding and plasma‑stabilizing intramolecular folds (2‑4). Mature human FGF‑23 contains an atypical (very low affinity) heparin binding site (aa 134‑162), a proteolytic cleavage site (Arg179‑Ser180), and multiple O‑linked glycosylation sites with Thr178 being of particular importance (4‑7). O‑linked glycosylation at Thr178 blocks the cleavage of FGF‑23, thereby preventing loss of FGF‑23 activity (7, 8). Mature human FGF‑23 shows 72% aa identity to mouse FGF‑23 and is active on mouse cells (6). FGF‑23 exerts its effects through a ternary complex that includes Klotho and an FGF receptor (FGF R4 or the "c" isoforms of FGF R1 or FGF R3). Klotho has a restricted distribution that limits FGF‑23 activity (9‑11). FGF‑23 is produced by osteocytes and osteoblasts in response to high circulating phosphate levels, elevated parathyroid hormone, and circulatory volume loading. It functions as an endocrine phosphatonin by suppressing circulating phosphate levels (12). FGF‑23 interaction with renal proximal tubular epithelium decreases the renal resorption of phosphate by down‑regulating phosphate transporters and by suppressing vitamin D production. It also decreases the intestinal absorption of phosphate (13).

References
  1. Mohammadi, M. et al. (2005) Cytokine Growth Factor Rev. 16:107.
  2. Fukumoto, S. (2007) Endocr. J. Sep 14; [Epub ahead of print].
  3. Goetz, R. et al. (2007) Mol. Cell. Biol. 27:3417.
  4. Harmer, N.J. et al. (2004) Biochemistry 43:629.
  5. Yamashita, T. et al. (2000) Biochem. Biophys. Res. Commun. 277:494.
  6. Shimada, T. et al. (2001) Proc. Natl. Acad. Sci. USA 98:6500.
  7. Frishberg, Y. et al. (2007) J. Bone Miner. Res. 22:235.
  8. Kato, K. et al. (2006) J. Biol. Chem. 281:18370.
  9. Zhang, X. et al. (2006) J. Biol. Chem. 281:15694.
  10. Urakawa, I. et al. (2006) Nature 444:770.
  11. Kurosu, H. et al. (2006) J. Biol. Chem. 281:6120.
  12. Razzaque, M.S. and B. Lanske (2007) J. Endocrinol. 194:1.
  13. Kurosu, H. et. al. (2007) J. Biol. Chem. 282:26687.
Long Name
Fibroblast Growth Factor 23
Entrez Gene IDs
8074 (Human); 64654 (Mouse)
Alternate Names
ADHR; FGF23; FGF-23; fibroblast growth factor 23; HPDR2; HYPF; phosphatonin; PHPTC; tumor-derived hypophosphatemia inducing factor; Tumor-derived hypophosphatemia-inducing factor

Citations for Recombinant Human FGF-23 Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

19 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Molecular Interaction of Soluble Klotho with FGF23 in the Pathobiology of Aortic Valve Lesions Induced by Chronic Kidney Disease
    Authors: The, E;Zhai, Y;Yao, Q;Ao, L;Fullerton, DA;Meng, X;
    International journal of biological sciences
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. ERR?-inducible FGF23 promotes alcoholic liver injury through enhancing CYP2E1 mediated hepatic oxidative stress
    Authors: Jung, YS;Radhakrishnan, K;Hammad, S;Müller, S;Müller, J;Noh, JR;Kim, J;Lee, IK;Cho, SJ;Kim, DK;Kim, YH;Lee, CH;Dooley, S;Choi, HS;
    Redox biology
    Species: Mouse, Transgenic Mouse
    Sample Types: In Vivo
    Applications: In vivo assay
  3. A New Approach to the Quantification of Fibroblast Growth Factor 23-An Array Surface Plasmon Resonance Imaging Biosensor
    Authors: Tokarzewicz, A;O?dak, ?;M?ynarczyk, G;Klekotka, U;Gorodkiewicz, E;
    International journal of molecular sciences
    Species: Human, N/A
    Sample Types: Plasma, Recombinant Protein
    Applications: Surface Plasmon Resonance
  4. Mutations in an unrecognized internal NPT2A PDZ motif disrupt phosphate transport causing congenital hypophosphatemia
    Authors: WB Sneddon, PA Friedman, T Mamonova
    bioRxiv : the preprint server for biology, 2023-03-07;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. RGS14 regulates hormone-sensitive NPT2A-mediated renal phosphate uptake via binding to the NHERF1 scaffolding protein
    Authors: PA Friedman, WB Sneddon, T Mamonova, C Montanez-M, S Ramineni, NH Harbin, KE Squires, JV Gefter, CE Magyar, DR Emlet, JR Hepler
    The Journal of Biological Chemistry, 2022-03-17;0(0):101836.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Bone marrow sinusoidal endothelium controls terminal erythroid differentiation and reticulocyte maturation
    Authors: J Heil, V Olsavszky, K Busch, K Klapproth, C de la Torr, C Sticht, K Sandorski, J Hoffmann, H Schönhaber, J Zierow, M Winkler, CD Schmid, T Staniczek, DE Daniels, J Frayne, G Metzgeroth, D Nowak, S Schneider, M Neumaier, V Weyer, C Groden, HJ Gröne, K Richter, C Mogler, MM Taketo, K Schledzews, C Géraud, S Goerdt, PS Koch
    Nature Communications, 2021-11-29;12(1):6963.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Structure-function relationships of the soluble form of the antiaging protein Klotho have therapeutic implications for managing kidney disease
    Authors: X Zhong, S Jagarlapud, Y Weng, M Ly, JC Rouse, K McClure, T Ishino, Y Zhang, E Sousa, J Cohen, B Tzvetkova, K Cote, JJ Scarcelli, K Johnson, J Palandra, JR Apgar, S Yaddanapud, RG Villalobos, AC Opsahl, K Lam, Q Yao, W Duan, A Sievers, J Zhou, D Ferguson, A D'Antona, R Zollner, HL Zhu, R Kriz, L Lin, V Clerin
    J. Biol. Chem., 2020-01-31;0(0):.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Cell Culture
  8. FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis
    Authors: I Böckmann, J Lischka, B Richter, J Deppe, A Rahn, DC Fischer, J Heineke, D Haffner, M Leifheit-N
    Int J Mol Sci, 2019-09-18;20(18):.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Bioassay
  9. Prolonged exposure to 1,25(OH)2D3 and high ionized calcium induces FGF-23 production in intestinal epithelium-like Caco-2 monolayer: A local negative feedback for preventing excessive calcium transport
    Authors: M Rodrat, K Wongdee, N Panupinthu, J Thongbunch, J Teerapornp, N Krishnamra, N Charoenpha
    Arch. Biochem. Biophys., 2018-01-06;640(0):10-16.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Fibroblast growth factor 23 weakens chemotaxis of human blood neutrophils in microfluidic devices
    Authors: K Yang, H Peretz-Sor, J Wu, L Zhu, X Cui, M Zhang, C Rigatto, Y Liu, F Lin
    Sci Rep, 2017-06-08;7(1):3100.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. ?-Klotho expression determines nitric oxide synthesis in response to FGF-23 in human aortic endothelial cells
    Authors: CP Chung, YC Chang, Y Ding, K Lim, Q Liu, L Zhu, W Zhang, TS Lu, G Molostvov, D Zehnder, LL Hsiao
    PLoS ONE, 2017-05-02;12(5):e0176817.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  12. Convergent Signaling Pathways Regulate Parathyroid Hormone and Fibroblast Growth Factor-23 Action on NPT2A-mediated Phosphate Transport
    J Biol Chem, 2016-07-18;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Regulation of CYP27B1 mRNA Expression in Primary Human Osteoblasts
    Authors: K van der Me, HW van Essen, FW Bloemers, EA Schulten, P Lips, N Bravenboer
    Calcif Tissue Int, 2016-03-25;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium.
    Authors: Six I, Okazaki H, Gross P, Cagnard J, Boudot C, Maizel J, Drueke T, Massy Z
    PLoS ONE, 2014-04-02;9(4):e93423.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  15. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis.
    Authors: Coe, Lindsay, Madathil, Sangeeth, Casu, Carla, Lanske, Beate, Rivella, Stefano, Sitara, Despina
    J Biol Chem, 2014-02-07;289(14):9795-810.
    Species: Mouse
    Sample Types: In Vivo, Whole Cells
    Applications: Bioassay, In Vivo
  16. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319.
    Authors: Kharitonenkov, Alexei, Beals, John M, Micanovic, Radmila, Strifler, Beth A, Rathnachalam, Radhakri, Wroblewski, Victor J, Li, Shun, Koester, Anja, Ford, Amy M, Coskun, Tamer, Dunbar, James D, Cheng, Christin, Frye, Christop, Bumol, Thomas F, Moller, David E
    PLoS ONE, 2013-03-11;8(3):e58575.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  17. Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia.
    Authors: Wu, Ai-Luen, Feng, Bo, Chen, Mark Z, Kolumam, Ganesh, Zavala-Solorio, Jose, Wyatt, Shelby K, Gandham, Vineela, Carano, Richard, Sonoda, Junichir
    PLoS ONE, 2013-02-22;8(2):e57322.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Bioassay
  18. Circulating alphaKlotho influences phosphate handling by controlling FGF23 production.
    Authors: Smith R
    J. Clin. Invest., 2012-11-26;122(12):4710-5.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  19. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer.
    Authors: Tomlinson DC, Knowles MA
    Am. J. Pathol., 2010-10-01;177(5):2379-86.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs
Loading...

Reviews for Recombinant Human FGF-23 Protein

There are currently no reviews for this product. Be the first to review Recombinant Human FGF-23 Protein and earn rewards!

Have you used Recombinant Human FGF-23 Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review